Posted by Michael Wonder on 30 Apr 2018
Brexit diagnosis predicts drug delay for UK patients
28 April 2018 - One of Scotland’s leading neurologists has warned that Brexit will delay the newest life-saving drugs reaching patients in the UK.
Professor Malcolm Macleod said that EU withdrawal will make it less likely that pharmaceutical companies developing new treatments turn to Britain when it comes to drug approval.
Macleod said that delays could prove critical for patients facing life-threatening diseases. According to Macleod, Brexit would see the UK lose out to the rest of the EU when it came to drugs companies choosing the markets to introduce their drugs.
